Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 9/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | IDH2 | P48735 | 3/20 | 0.38 |
| ▸ | GPR39 | O43194 | 2/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | AQP1 | P29972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15102463 | 0.86 | IDH1 (0.51) | IDH1GBA1SMN1; SMN2ALDH1A1IDH2 | |
| SCHEMBL16388574 | 0.84 | IDH1 (0.44) | IDH1IDH2 | |
| SCHEMBL16388552 | 0.81 | ROCK1 (0.49) | IDH1IDH2 | |
| SCHEMBL16392134 | 0.79 | SMN1; SMN2 (0.41) | IDH1GBA1SMN1; SMN2ALDH1A1IDH2 | |
| SCHEMBL16388779 | 0.78 | USP2 (0.48) | SMN1; SMN2ALDH1A1CNR1 | |
| SCHEMBL16388427 | 0.75 | IDH1 (0.50) | IDH1IDH2 | |
| SCHEMBL16388455 | 0.74 | CDK9 (0.54) | IDH1SMN1; SMN2ALDH1A1IDH2 | |
| SCHEMBL16388782 | 0.73 | ROCK1 (0.47) | IDH1IDH2 | |
| SCHEMBL16388184 | 0.71 | ROCK1 (0.47) | — | |
| SCHEMBL16388192 | 0.71 | IDH1 (0.50) | IDH1IDH2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019490-B1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20170348318-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2017-12-07 | — | — | US | disclosed |
| US-9724350-B2 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160158241-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| WO-2015006592-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158241-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | IDH1 4/4885GBA1 2315/4885SMN1; SMN2 2743/4885 |
| US-20170348318-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | IDH1 4/4885GBA1 2315/4885SMN1; SMN2 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.